

# Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis

Matteo Trimarchi<sup>1</sup>, Pietro Indelicato<sup>2</sup>, Alessandro Vinciguerra<sup>2</sup>, and Mario Bussi<sup>2</sup>

<sup>1</sup>Affiliation not available

<sup>2</sup>San Raffaele Hospital

December 2, 2020

## Abstract

Chronic rhinosinusitis with nasal polyps is a type 2-mediated inflammatory disease associated with significant burden due to symptoms and high recurrence rate after surgery. Dupilumab, a monoclonal antibody against the interleukin-4 receptor subunit  $\alpha$ , has demonstrated good clinical efficacy and acceptable safety in phase II and phase III trials.

## Hosted file

Manuscript.pdf available at <https://authorea.com/users/380664/articles/496563-clinical-efficacy-of-dupilumab-in-the-treatment-of-severe-chronic-rhinosinusitis>





